EMA starts continual assessment of Sanofi's corona vaccine

The European Medicines Agency has now started to assess Sanofi's coronavirus vaccine frequently, to ensure faster authorization of the jab if it lives up to the authority's requirements.

Photo: Frank Hoermann/AP/Ritzau Scanpix

Another covid-19 vaccine has come a step closer to approval.

The European Medicines Agency (EMA) reported on Tuesday that it had started to continually assess Sanofi's covid-19 vaccine, Vidprevtyn.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs